A Phase 1/2 Study of Oral MRT-2359 in Selected Cancer Patients
Status:
Not yet recruiting
Trial end date:
2027-11-01
Target enrollment:
Participant gender:
Summary
This Phase 1/2, open-label, multicenter study is conducted in patients with previously
treated selected solid tumors, including non-small cell lung cancer (NSCLC), small cell lung
cancer (SCLC), high-grade neuroendocrine cancer of any primary site, diffuse large B-cell
lymphoma (DLBCL), and tumors with L-MYC or N-MYC amplification. Patients receive escalating
doses of a GSPT1 molecular glue degrader MRT-2359 to determine safety, tolerability, maximum
tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of MRT-2359. Once the MTD and/or
RP2D is identified, additional patients enroll to Phase 2 study, which includes molecular
biomarkers stratification or selection, namely mRNA expression or amplification of L-MYC and
N-MYC genes.